论文部分内容阅读
目的 :了解伴有贫血的恶性肿瘤患者血清红细胞生成素 (EPO)水平的变化。方法 :用酶联免疫法(ELISA)检测 40例伴有贫血的恶性实体瘤患者及 2 3名正常人 (对照组 ) ,血清EPO水平。结果 :肿瘤患者红细胞平均体积 (MCV)为 (83 5 1± 7 92 )fL ,红细胞平均血红蛋白浓度 (MCHC)为 0 3 0± 0 0 6,肿瘤患者和对照组EPO水平分别为 (3 6 0 6± 2 1 88)IU/L和 (11 5 0± 7 3 7)IU/L(P <0 0 5 ) ,40例患者有 3 2例EPO水平高于正常 ,占 80 %。IV期患者和其他期别患者EPO水平分别为 (4 4 3 8± 18 3 6)IU /L和 (2 0 5 9± 19 80 )IU/L ,P <0 0 5 ,血红蛋白浓度分别为 (95 67± 2 3 89)× 10 12 /L和 (10 9 93± 2 1 5 1)× 10 12 /L ,P >0 0 5。结论 :恶性肿瘤患者表现为正常细胞低色素和小细胞低色素性贫血 ,贫血呈多样化改变。 80 %贫血肿瘤患者血清EPO水平异常增高 ,且晚期患者EPO水平增高更明显。
Objective: To understand the changes of serum erythropoietin (EPO) levels in patients with anemia associated with malignancy. Methods: Enzyme linked immunosorbent assay (ELISA) was used to detect the levels of EPO in 40 anemia solid tumor patients and 23 healthy controls (control group). Results: The average volume of erythrocytes (MCV) was (83 5 1 ± 7 92) fL and the mean erythrocyte hemoglobin (MCHC) was 0 30 ± 0 0 6 in cancer patients. The levels of EPO in tumor patients and control group were 6 ± 2 1 88) IU / L and (11 5 0 ± 7 3 7) IU / L (P 0 05). There were 32 patients with EPO levels higher than normal in 80 patients (80%). The EPO levels of patients with stage IV and other stages were (443 ± 1836) IU / L and (2559 ± 1980) IU / L, respectively, P <0 05 and the hemoglobin concentrations were ( 95 67 ± 2 3 89) × 10 12 / L and (10 9 93 ± 2 1 5 1) × 10 12 / L, P> 0 0 5. CONCLUSIONS: Malignant tumors show normal and hypocytic hypochromic anemia with varying anemia. In 80% of patients with anemia, serum levels of EPO are abnormally elevated, and the levels of EPO in advanced patients are more obvious.